Nemea Therapeutics is a preclinical-stage company developing oral small molecule inhibitors targeting mitochondrial RNA polymerase (POLRMT) for the treatment of mitochondria-dependent solid tumors.
Annoviant is advancing patient outcomes in heart disease by delivering innovative, regenerative cardiovascular devices built on its proprietary TxGuard™ soft-tissue technology.
The platform enables durable, off-the-shelf solutions that address critical unmet needs in heart valve disease and coronary artery bypass grafting—helping patients live healthier lives while reducing long-term healthcare costs.
Avast Therapeutics is developing first-in-class, non-invasive peptide therapeutics that safely cross the blood-brain barrier to restore mitochondrial function and protect neurons.
This breakthrough approach targets neurodegenerative diseases such as Parkinson’s and Alzheimer’s at their earliest stages, with the potential to halt disease progression and transform brain medicine.
Bluegrass Pharmaceuticals develops advanced Lipid Nanoparticles (LNPs) to enhance vaccine efficacy and enable targeted therapeutic delivery.
Kifa Therapeutics advances highly selective CNS-kinase inhibitors, starting with a G2019S-LRRK2 therapy for Parkinson’s disease.
Our strategy pairs genetics-based patient selection with validated biomarkers to enable efficient clinical studies and an orphan, accelerated-approval path.
SelSym Biotech is pioneering hemostasis with SymClot, an innovative platelet-mimetic therapy that promises to dramatically improve patient survival and outcomes by rapidly stopping bleeding after severe trauma and high-risk surgeries.
Moonlight Therapeutics is a clinical-stage biotech company developing MOON101, a novel microneedle stamp treatment for peanut allergy that delivers allergen proteins directly into the skin to safely desensitize the immune system.
At Myosin Therapeutics, we’re tackling aggressive, treatment-resistant cancers by targeting a completely new frontier in cancer biology—the molecular nanomotors that power cancer cell movement, invasion, and survival.
PHIOGEN is a pre-clinical-stage biotechnology company developing first-in-class immunizing therapeutics designed to both treat drug-resistant infections and induce durable immune protection against recurrence, with a focus on chronic conditions.
Neurodiverse Technologies develops adaptive, research-driven simulation platforms that empower neurodivergent individuals to build real-world readiness and confidence.
Our products—including SANDI for driver readiness and NAVIS for interview and employment preparation—combine neuroscience, virtual reality, and machine learning to create accessible, data-informed training environments.
As a Vanderbilt University spin-off, we bridge academic innovation and real-world impact, helping individuals gain independence while enabling institutions to deliver evidence-based readiness programs at scale.
